Hormone Therapy for Lung Cancer Port Chester NY

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Local Companies

Phelps Memorial Hospital Cntr
914-366-3000
701 North Broadway
Sleepy Hollow, NY
Mount Vernon Hospital
914-664-8000
12 North Seventh Avenue
Mount Vernon, NY
Sound Shore Medical Center
914-632-5000
16 Guion Place
New Rochelle, NY
Winthrop-University Hospital
516-663-0333
259 First Street
Mineola, NY
Englewood Hosp & Medical Ctr
201-894-3000
350 Engle Street
Englewood, NJ
Veterans Affairs Med Center
631-261-4400
79 Middleville Road
Northport, NY
Westchester Medical Center
914-493-7000
Valhalla Campus
Valhalla, NY
Jacobi Medical Center
718-918-5000
1400 Pelham Parkway
Bronx, NY
St Barnabas Hospital
718-960-9000
183rd Street & Third Avenue
Bronx, NY
Pascack Valley Hospital
201-358-3000
250 Old Hook Road
Westwood, NJ
Data Provided by:
  

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Prostate Cancer Port Chester NY
Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.
- Breast Cancer Treatment Port Chester NY
- Drug Combo Proves Powerful Against Lung Cancer Port Chester NY
- Hormone Therapy Port Chester NY
- Hormone Therapy for Breast Cancer Port Chester NY
- Hormone Therapy for Early Prostate Cancer Port Chester NY
- Menopausal Hormone Therapy Port Chester NY
- Delayed Prostate Cancer Therapy Port Chester NY
- Head and Neck Cancer Treatment Port Chester NY